(DUSA, ASTC, CRWE, VRML) PennyOmega.com Stocks In Action

DUSA, DUSA Pharmaceuticals, Inc. ** For the fourth quarter 2011, DUSA posted total product revenues of $15.3 million, a 29% increase year over year, and net income of $3.3 million, or $0.13 per common share on a diluted basis, compared to $2.9 million, or $0.12 per common share on a diluted basis, in the same period the prior year. DUSA’s net income for the full year 2011 was $7.3 million, or $0.28 per common share on a diluted basis, compared to net income of $2.7 million, or $0.11 per common share in 2010. DUSA is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) PDT technology platform. Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution, 20% plus blue light illumination using DUSA’s BLU-U Blue Light Photodynamic Therapy Illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. More about DUSA at www.dusapharma.com. ***************** ASTC, Astrotech Corporation ASTC’s subsidiary 1st Detect Corporation reported that the European Patent Office (EPO) has issued a key patent for the company’s unique method to drive a mass spectrometer ion trap used for chemical analysis and detection. The patent, entitled “Driving a Mass Spectrometer Ion Trap or Mass Filter,” represents a key technological advantage for ASTC’s 1st Detect to optimize the operation of an ion trap using compact and efficient circuitry. 1st Detect Corporation has developed an instrument that revolutionizes the chemical detection and analysis market by delivering lab performance mass spectrometry in a small, affordable and easily portable package. The 1st Detect mini mass spectrometer’s broad capabilities make it an ideal tool for a variety of applications in the research, security, industrial, process flow and healthcare markets; and is capable of detecting a wide variety of chemicals including residues and vapors from explosives, chemical warfare agents, toxic chemicals, food and beverage contaminants and pollution products. ASTC formed 1st Detect Corporation to develop and commercialize miniature-mass spectrometer technology first developed under an agreement with NASA for use on the International Space Station. ASTC is one of the first space commerce companies and remains a strong entrepreneurial force in the aerospace industry. More bout ASTC at www.astrotechcorp.com ***************** CRWE, Crown Equity Holdings Inc., CRWE.OB ** With expertise in online solutions and marketing, CRWE recently launched CRWE Real Estate (www.crwerealestate.com) to provide a global portal for property listings at a fee of only $1 a day. The other is CRWE Direct (www.crwedirect.com), an online business-to-business (B2B) marketplace for manufacturers and small to large businesses to purchase various types of merchandise. Manufacturers may start downloading their product immediately, free of charge during the next six months. Thereafter, there will be various annual fees. The listing process and image loading for both sites are user-friendly. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. CRWE’s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. More about CRWE at www.crownequityholdings.com. ***************** VRML, Vermillion, Inc. ** VRML reported that the American Medical Association (AMA) Current Procedural Terminology (CPT) Panel has voted to approve an application for a Category 1 CPT code for its OVA1(R) test, which is designed to help differentiate benign versus malignant ovarian-masses. VRML is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. More about VRML at www.vermillion.com. ******************************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.